Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.03 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• BofA lists top 5 themes driving next $1tn in incremental semi sales